TY - JOUR T1 - The Factor V Leiden variant and risk of chronic thromboembolic pulmonary hypertension JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00774-2020 VL - 56 IS - 4 SP - 2000774 AU - Mark W. Dodson AU - Kelli Sumner AU - Jadyn Carlsen AU - Meghan M. Cirulis AU - Emily L. Wilson AU - Abhishek Gadre AU - Timothy M. Fernandes AU - Lynette M. Brown AU - D. Hunter Best AU - C. Gregory Elliott Y1 - 2020/10/01 UR - http://erj.ersjournals.com/content/56/4/2000774.abstract N2 - Chronic thromboembolic pulmonary hypertension (CTEPH) is a devastating complication that occurs in about 3% of survivors of acute pulmonary embolism (PE) [1]. Genetic risk factors may differentiate patients with acute PE who develop CTEPH from those who do not develop CTEPH. The Factor V Leiden (FVL) and Prothrombin G20210A (PT) variants are the most common genetic risk factors for venous thromboembolism (VTE) [2, 3]. In European CTEPH patients, the frequencies of these variants are not increased compared with either patients with non-CTEPH pulmonary hypertension or healthy controls [4–7]. While these data suggest that genetic risk factors for CTEPH and PE may be distinct [8], no studies have directly compared the frequencies of these variants in patients with CTEPH and patients with acute PE who did not develop CTEPH.The Factor V Leiden variant is identified significantly less frequently among CTEPH patients who had their first venous thromboembolism prior to 50 years of age than among similar patients with acute pulmonary embolism who did not develop CTEPH https://bit.ly/2W6qoLKThe authors wish to thank Scott Stevens and Scott Woller (Dept of Medicine, Intermountain Medical Center, Murray, Utah) for help in enrolling PE patients in the thrombosis clinic at Intermountain Medical Center. ER -